BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

A New Super-Quenching Fluorescence-Based Assay For HTS And Drug Discovery From QTL Biosystems, LLC


10/19/2005 5:09:29 PM

SANTA FE, N.M., Dec. 10 /PRNewswire/ -- QTL Biosystems, LLC, a provider of innovative products for bio-detection, drug discovery, and life science research, announced today the release of the QTL LIGHTSPEED(TM) Caspase-3 Assay Kit. This assay utilizes a proprietary fluorescent polyelectrolyte- based super-quenching polymer that offers a significant advantage compared to conventional small molecule fluorescence. The QTL LIGHTSPEED platform provides single-step, instantaneous, homogenous assays, and addresses a broad spectrum of drug targets in high-throughput screening.

QTL Biosystems product applies its novel QTL LIGHTSPEED platform to Caspase-3 research. Caspase-3 is part of the Apoptosis (programmed cell death) intracellular process. Apoptosis can play a significant role in disease when it is either excessive or insufficient. Because of their roles in inflammation and apoptosis, the caspases have received enormous research interest. The QTL LIGHTSPEED Caspase-3 assay combines high sensitivity with high speed for screening of potential inhibitors against Caspase-3.

"The QTL LIGHTSPEED Caspase-3 Assay Kit generates a large signal, thus researchers are able to generate results that offer enhanced sensitivity, quicker time to results, and greater signal to noise, even at the highest throughput rates and plate densities," notes Duncan McBranch, Ph.D. Co-founder and President at QTL Biosystems.

"Researchers will soon be able to harness this technology to screen for multiple drug targets and compound libraries," stated David Whitten, Ph.D. Co-founder and CTO at QTL Biosystems.

Fluorescence-based assays are among the most important screening techniques used in pharmaceutical drug discovery. A technique commonly used is FRET (fluorescence resonance energy transfer). FRET reactions typically couple a single fluorophore with a single quencher molecule.

In contrast, QTL LIGHTSPEED ("QTL" stands for "quencher-tether-ligand") couples a quencher molecule with a fluorescent polymer chain. Each quencher alters fluorescence of several hundred fluorophores thus leading to enhanced sensitivities. QTL's technology offers a significant performance advantage enabling greater sensitivity, specificity, shorter time to results, and material cost savings.

About QTL Biosystems

QTL Biosystems, LLC is a supplier of amplification technologies for bioassays that accelerate and improve drug discovery, bio-detection, and other life sciences research. The Company's assay solutions facilitate the high throughput and cost-effective identification and evaluation of drug candidates. The Company's advanced core technologies integrate its expertise in chemistry, molecular and cell biology and instrumentation. QTL Biosystems enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs.

Contact: Paul Gindlesperger Director of Sales and Marketing QTL Biosystems, LLC 2778 Agua Fria Street Santa Fe, NM 87507 (505) 424-1000, ext. 116 pgindlesperger@qtlbio.comhttp://www.qtlbio.com/

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com/.

QTL Biosystems, LLC

CONTACT: Paul Gindlesperger, Director of Sales and Marketing,QTL Biosystems, LLC, +1-505-424-1000, ext. 116, pgindlesperger@qtlbio.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES